Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease

Press release of the Vivoryon Therapeutics AG / April 16, 2020

A meprin protease inhibitor and assay platform developed at Fraunhofer IZI are the basis for the research collaboration with Vivoryon Therapeutics AG. Headed by PD Dr. Stephan Schilling, the Department of Drug Design and Target Validation will work with the company to develop first-class small molecule meprin inhibitors. The aim is to develop therapeutic applications for fibrosis, cancer and Alzheimer's disease.